MedTrace Logo

Registry of COVID-19 Patients Treated With the Seraph 100 Microbind Affinity Blood Filter

NCT04361500 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 100

Last updated 2020-04-24

No results posted yet for this study

Summary

The purpose of this registry study is to investigate the effectiveness and safety of the Seraph® 100 Microbind® Affinity Blood Filter (Seraph 100) in the treatment of COVID-19 patients.

Conditions

Interventions

DEVICE

Seraph 100

Seraph 100 therapy during a COVID-19 infection

Sponsors & Collaborators

  • Medical Clinic V Nephrology, Academic Teaching Hospital Brunswick

    collaborator UNKNOWN

  • Hannover Medical School

    lead OTHER

Eligibility

Min Age
18 Years
Max Age
99 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-04-15
Primary Completion
2020-10-01
Completion
2021-10-01
FDA Device
Yes

Countries

  • Germany

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04361500 on ClinicalTrials.gov